📰 Mark Swallow News
Page 5 - Mark Swallow News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Mark Swallow. Real-time updates on events, politics, business and more.
September 12, 2022
EO2401 is a first-in-class OncoMimics therapeutic cancer vaccine able to significantly expand existing effector memory CD8+ T cells directed at OncoMimics peptides corresponding to tumor-associated
September 6, 2022
/PRNewswire/ -- Coave Therapeutics (Coave), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central...
September 6, 2022
Enterome is evaluating EO2401 in Phase 1/2 clinical trials in recurrent glioblastoma (ROSALIE) and adrenocortical malignancies (SPENCER) Proof-of-concept data...
September 6, 2022
Enterome is evaluating EO2401 in Phase 1/2 clinical trials in recurrent glioblastoma (ROSALIE) and adrenocortical malignancies (SPENCER)Proof-of-concept data in both trials of EO2401 have demonstrated
July 18, 2022
Enterome and Nestlé Health Science will co-develop Enterome's lead EndoMimics compound, EB1010, a potent local inducer of IL-10 targeting food allergies and inflammatory bowel disease (IBD).
June 30, 2022
/PRNewswire/ -- Coave Therapeutics (Coave), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central...
June 9, 2022
Investegate announcements from Acacia Pharma Group plc, Scheme of arrangement becoming effective
June 9, 2022
09.06.2022 - Acacia Pharma Group PLC THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE ...
May 27, 2022
World first clinical data of EO2401, Enterome's first-in-class off-the-shelf OncoMimics therapeutic cancer vaccine, to be presented PARIS, May 27, 2022 /PRNewswire/ -- Enterome, a clinical
May 23, 2022
PARIS, May 23, 2022 /PRNewswire/ -- Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform